| 0.37 0.01 (2.78%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.51 |
1-year : | 0.6 |
| Resists | First : | 0.43 |
Second : | 0.51 |
| Pivot price | 0.37 |
|||
| Supports | First : | 0.35 |
Second : | 0.31 |
| MAs | MA(5) : | 0.36 |
MA(20) : | 0.37 |
| MA(100) : | 0.37 |
MA(250) : | 0.47  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.7 |
D(3) : | 34.3 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 0.98 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ VXRT ] has closed below upper band by 35.8%. Bollinger Bands are 11.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.36 - 0.36 | 0.36 - 0.36 |
| Low: | 0.33 - 0.34 | 0.34 - 0.34 |
| Close: | 0.36 - 0.36 | 0.36 - 0.36 |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Sun, 30 Nov 2025
Vaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell? - MarketBeat
Sat, 15 Nov 2025
Vaxart, Inc. (NASDAQ:VXRT) Q3 2025 Earnings Call Transcript - Insider Monkey
Fri, 14 Nov 2025
Vaxart, Precigen gain after Q3 2025 results (VXRT) - Seeking Alpha
Thu, 13 Nov 2025
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results - Yahoo Finance
Thu, 13 Nov 2025
Vaxart (VXRT) Secures $700 Million Partnership with Dynavax - GuruFocus
Thu, 13 Nov 2025
Vaxart Inc (VXRT) Q3 2025 Earnings Call Highlights: Strategic Partnership and Revenue Surge ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 229 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 21,170 (K) |
| Shares Short P.Month | 14,350 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.7 |
| PEG Ratio | 0 |
| Price to Book value | 1.5 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 12.18 |
| Forward Dividend | 0 |
| Dividend Yield | 3125.6% |
| Dividend Pay Date | 2024-12-19 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|